This review discusses recent studies that have implications for potential neuropharmacological interventions which target cognitive deficits resulting from traumatic brain injury or stroke.
Introduction
Acquired brain damage, following stroke or traumatic injury, often results in chronic cognitive deficits, commonly including disorders of memory, attention, executive function and language [1 -3 ,4-7] . All of these functions are critically important in day-to-day life, so the persistence of such deficits is a poor prognostic indicator for long-term functional independence. While traditional therapeutic approaches to rehabilitation have had some success in treating patients' motoric problems they have been far less successful in targeting cognitive deficits [3 ,8] .
Studies in both humans and animals have highlighted the importance of neurochemical modulation of normal cognitive function, such as dopamine in working memory and the cholinergic system in alertness and attention. Performance on cognitive tasks can be enhanced by targeting these processes using pharmacological agents [9, 10 ] . Such results suggest the possibility of using neuropharmacological interventions acutely to reduce loss of cognitive function, or chronically to treat established cognitive deficits. The clinical use of psychopharmacological interventions after brain injury is still very much in its preliminary stages, however, and unfortunately many of the studies in the literature are anecdotal or poorly controlled.
Although in excess of 100 different neurotransmitters have been identified within the mammalian brain only a few have been found to play an especially critical role in the performance of cognitive tasks [11] . Table 1 summarizes the main neurotransmitters discussed within the current review and outlines the major cognitive functions with which they have been linked. It is immediately evident that each of these neurotransmitters contributes to a range of different cognitive functions and that many of these functions are dependent on the action of multiple transmitter systems. Additionally, it is possible that some of the putative cognitive effects of these neurotransmitters are secondary to their effects on other cognitive systems; for example, an effect on memory tasks may arise from modulation of arousal or attention. The large range of functions in which these transmitters are implicated is reflected anatomically in their wide distribution across many different brain regions.
Nonetheless, studies of cognitive deficits in patients with chronic neurodegenerative disease have led to the identification of potentially critical neurotransmitter pathways and to the development of pharmacological compounds that target the action of specific transmitters. For example, considerable interest has been directed towards ascending projections from neurons containing acetylcholine in the nucleus basalis of Meynert of the basal forebrain. Patients with Alzheimer's disease exhibit substantial degeneration within this region which sends widespread projections to the frontal, temporal and parietal lobes. Animal models of Alzheimer's produced by lesioning this structure have demonstrated deficits in learning and memory, which can to an extent be ameliorated by pharmacological intervention (e.g. by the use of the acetylcholinesterase inhibitor physostigmine). Similarly, there is a large body of evidence for the existence of cognitive deficits in patients with Parkinson's disease, who exhibit considerable depletion of dopamine production within their nigrostriatal system as well as a substantial reduction of norepinephrine production in the locus coreleus, which projects to many cortical regions.
The current review aims to highlight recent advances in our understanding of the links between psychopharmacology and impaired cognitive function. Specifically, we focus on studies of pharmacological compounds that offer a promising basis for either the preservation of cognitive function, or the treatment of chronic cognitive deficits. We consider evidence from clinical trials in humans that have targeted cognitive deficits following stroke and traumatic brain injury (TBI), as well as animal models of acquired brain damage.
The role of glutamate in neuronal death and chronic cognitive deficits An important factor affecting the neurological outcome after stroke or TBI is the extent of delayed neuronal death. Both ischemic and traumatic injury results in an increase in excitatory amino acid (including glutamate) efflux in the brain. It is commonly believed that glutamate activation of N-methyl-D-aspartate (NMDA) receptors results in a calcium and sodium ion influx into the cell that leads to excitotoxic neuronal death [12] [13] [14] . Therefore, researchers have attempted to reduce neuronal death by intervention with compounds that act as NMDA receptor antagonists [15] [16] [17] [18] [19] .
For example, it has been proposed that the neuroprotective effect of small quantities of caffeine and alcohol may result from the blockade of adenosine A2A receptors (by caffeine) and NMDA receptors (by ethanol) which leads to a decrease in the release of, and postsynaptic response to, glutamate [20] . Several studies [20] [21] [22] [23] [24] have examined the effectiveness of the co-administration of low doses of caffeine and ethanol after acquired brain damage. Initially, assessed in animal models of stroke, the efficacy of this combination treatment for TBI was recently assessed by Dash and colleagues [20] . They found that when administered 15 min after trauma, rats showed reduced cortical contusion volume and improved working memory (indexed by the ability to retain a simple condition response task, in which a tone was followed by a shock, over 24 h). The time window for treatment is extremely short, however, and, for example, it has proven ineffective in human stroke patients if administered more than 3 h after their infarct [23] .
Recently, Biegon and colleagues [25 ] published an important study challenging the orthodox view of the role of glutamate in neuronal death. Their results help explain the short window of therapeutic efficacy for NMDA receptor antagonist treatments and suggest an important new direction for acute treatment of both stroke and TBI. Using a mouse model of TBI, these investigators demonstrated that hyperactivation of NMDA receptors is actually relatively short lived (<1 h) and is followed by a prolonged (>7 days) decrease in NMDA function. They therefore hypothesized that neurological and cognitive deficits could be minimized by stimulation -not antagonism -of NMDA receptors by the infusion of NMDA 1-2 days after trauma. Treated mice consistently performed significantly better than untreated mice in a battery of motor behaviour tasks and also in an object recognition test (Fig. 1) . Furthermore, the benefits of NMDA were entirely attenuated by co-administration of MK-801 (an NMDA antagonist) and 676 Trauma and rehabilitation mice in this condition performed significantly worse than the controls.
Biegon et al. concluded that humans with brain injury (stroke or TBI) were also likely to suffer from a prolonged decline in NDMA function. They proposed, therefore, that such patients might benefit from NMDA receptor agonist stimulation. Moreover, such treatment should have a relatively long time window (>24 h). Importantly for future trials, they argued that the use of NMDA antagonists could be actively harmful if employed beyond the acute injury phase. Establishing the precise time course of NMDA function after injury in humans remains a critical outstanding issue, however, affecting the application of either type of intervention. Nonetheless, the use of NMDA agonists remains a very promising potential treatment requiring clinical trials in TBI and stroke patients.
Targeted cognitive and neuronal protection in the acute setting A further cause of neuronal death is loss of oxygen and glucose resulting from the reduction in blood supply to undamaged neuronal populations. In stroke it may be possible to save hypoperfused neurons outside the initial area of ischemic damage by thrombolytic therapy. This is only effective if treatment is initiated shortly (<3-6 h) after stroke. Several studies have indicated, in animal models at least, that psychopharmacological interventions can reduce neuronal loss [20,21,25 -27 ,28] . Furthermore, some suggest that it is possible to protect, or aid the recovery of, cognitive functions by targeting specific neurotransmitter systems.
A recent study [26 ] demonstrated that it that may be possible to partially protect the cholinergic system after ischemic injury by the use of cholinesterase inhibitors. In principle, cholinesterase inhibitors could have a protective effect against neuronal death either by improving neuronal blood flow or through potentiation of nerve growth factors. In addition, because the synthesis and transport of acetylcholine are known to be disrupted by brain injury, such compounds might also contribute to the preservation or recovery of cognitive systems.
Borlongan and colleagues [26
] administered methanesulfonyl fluoride (MSF), a cholinesterase inhibitor, for 14 days starting 24 h after surgical occlusion of the right middle cerebral artery. They found that for rats treated with MSF, learning and retention after 24 h in a simple paired association task was nearly the same as for uninjured animals, and significantly better than controls given sham treatment (peanut oil). Furthermore, although both MSF and sham treatment animals had similar volumes of infarction, the MSF animals possessed a higher number (>10-15%) of choline acetyltranferase-positive cells. In principle, therefore, treatment with MSF could help preserve the cholinergic system after human brain injury, with the window for the initiation of treatment potentially being much larger than for current therapies.
The use of drugs that target specific neurotransmitters may also allow differential treatment of brain regions, so that greater effects might be produced on specific brain areas and behavioural tasks. For example, improvements in spatial memory have been found by Kline and colleagues [27 ] using bromocriptine (a D2 agonist) to target the dopaminergic system in rats with induced TBI, which frequently results in hippocampal damage. Rats treated with bromocriptine 15 min before TBI were significantly faster than untreated animals at finding the hidden platform in a water-maze task and also had a greater number of surviving CA 3 hippocampal neurons. The investigators attributed this to the antioxidant properties of bromocriptine reducing TBI induced oxidative stress, which contributes to delayed neuronal death in TBI. Consistent with this suggestion they found lower levels of malondialdehyde, the end product of the oxidative deterioration of lipids, in several regions of the treated rats' brains. This is the first time such an effect has been reported for TBI, but further studies are required to see if benefits can be gained by treatment after injury. Results for the object memory test for uninjured mice (white bars) or brain-injured mice treated with placebo (pale grey) or N-methyl-Daspartate (NMDA; dark grey). The left three bars show baseline performance prior to head injury, when both items were novel and all groups showed unbiased exploration, spending approximately equal amounts of time on each object. The right side of the figure shows results on the same test 14 days after induced trauma when one (familiar) object was repeated from the baseline test (so this should be recalled and explored less often if memory is intact). The placebo treated mice displayed considerable memory impairment, but both the uninjured and NMDA treated mice demonstrated familiarity of the old object, showing a significantly greater tendency to explore the novel item. Adapted with permission from Biegon et al. [25 ] .
In contrast, a recent study by Zhao et al. [29] examined the effects of galantamine (another cholinesterase inhibitor) administered 4 days before and 21 days after induced ischemia. There was no difference between the rate of recovery for treated and untreated animals on a watermaze task that involved spatial learning and memory of the location of a submerged platform. Neither group of injured animals, however, exhibited a residual deficit in the task suggesting that the induced ischemic insult had little effect on the neuronal populations involved in performing the task and so the absence of an effect is perhaps unsurprising.
Pharmacological treatment of established cognitive deficits
Neuropharmacological intervention in chronic patients, long after their initial stroke or TBI, is based on the assumption that it is possible to increase the efficacy of surviving neuronal networks by modulating neurotransmitters linked to cognitive functions, or facilitation of neural plasticity through long-term potentiation. Importantly, enhancement of basic cognitive functions (e.g. memory and attention) may produce improvements in other cognitive systems with which they interact. For example, improvements in working memory might also help to improve language production or executive function.
As within acute intervention there has been considerable interest in the use of cholinesterase inhibitors due to the significance of the cholinergic system in learning, memory and arousal. For example, it was shown in patients with post-stroke aphasia that donepezil can improve a range of linguistic tasks involving lexicalsemantic processing and input-output phonology [30] . More recently, Zhang and colleagues [31] examined the effects donepezil on attention and memory deficits using a crossover design in a group of 18 patients with moderate-to-severe TBI. They found that donepezil enhanced performance of the Wechsler Memory Scale-III and Paced Auditory Serial Addition (which involves attention, working memory and processing speed). Furthermore, the improvement persisted through to the last testing session 14 weeks after the medication was stopped, suggesting that the treatment may have facilitated a long-term change in the cholinergic system. The degree to which these improvements led to practical benefits in day-to-day tasks requires further investigation.
In a subsequent study, Walker et al. [32] assessed 36 TBI patients treated with donepezil using the Functional Independence Measure Score, which includes practical measures of cognitive and motor outcome designed to quantify the patients' level of independence [33] . They found no significant difference between the donepezil group and control subjects. Nonetheless, these are relatively crude global behavioural measures and it remains possible that the improvements Zhang et al. found will lead to practical improvements on daily tasks that are specifically reliant on learning, alertness and memory.
Recently, Whyte and colleagues [34] have investigated methylphenidate, which operates on the catecholaminergic systems (both dopaminergic and noradrenergic), in 34 moderate to severe TBI patients. They reported improvements in processing speed, but no decline in accuracy, across a range of tasks. Although, they found no improvements in attention in formal tests there was an increase in caregivers' ratings of patients' attentiveness. Lee et al. [35] have also reported cognitive improvements across a range of tasks in TBI patient treated with methylphenidate, but changes in their placebo group in many of the tasks make interpretation difficult.
Finally two important proof-of-principle studies have demonstrated the potential that psychopharmacological compounds can under certain circumstances ameliorate the effects of two cognitive deficits that are extremely common following stroke: hemispatial neglect and aphasia.
Noradrenergic treatment of hemispatial neglect
Unilateral neglect is characterized by a failure to acknowledge stimuli, or events, on the side of space opposite the injured hemisphere: left hemispace in right hemisphere stroke patients. It has been argued, however, that the spatial bias in neglect may be exacerbated by interacting non-spatial deficits [36] . In particular, Robertson and colleagues showed that neglect patients have generalized vigilance deficit and that their neglect can be reduced by a non-spatial alerting tone [37] .
Malhotra and colleagues [38] hypothesized it might be possible to enhance vigilance using guanfacine, an a2 noradrenergic agonist previously used to treat hypertension but more recently found to modulate cognitive performance in monkeys and humans. The investigators wanted to explore whether any improvement in sustained attention mediated by guanfacine might lead to an improvement in spatial neglect. They used a placebo controlled crossover design in three right-hemisphere patients with chronic (>23 months) neglect. Patients were assessed six times on a battery of neglect, sustained attention and memory tasks. Space exploration was measured using a touch-screen display, with which patients were required to search for targets (total, 64) among distractors. Participants indicated the location of a target by touching it.
Following guanfacine, two patients found significantly more items in left space (Fig. 2) , moved further to explore a greater extent of the left side of the screen, and spent significantly longer performing the task. The third patient showed no effect of treatment. He was the only patient whose lesion extended into the dorsolateral prefrontal cortex, however, which is considered to be the critical site of action for the positive cognitive effects of guanfacine. The results indicate that enhancing patients' ability to sustain attention while exploring a visual scene can help to ameliorate some aspects of their neglect of contralesional space. Guanfacine appears to offer a potential treatment for neglect patients, perhaps particularly for those without damage to the dorsolateral prefrontal cortex. This is especially important given the prevalence of the syndrome and the relatively limited efficacy of traditional treatments [3 ] . Further clinical trials are required to assess the general applicability of these findings for large groups of acute and chronic patients.
Zolpidem and aphasia
Cohen and colleagues [39 ] recently reported an intriguing single case study demonstrating the amelioration of chronic (>3 years) expressive aphasia. The patient had a stroke affecting her left insula, putamen and superior temporal gyrus. Although, able to produce certain syllables she could not produce identifiable words; her comprehension was spared. Following ingestion of zolpidem (an agent prescribed for insomnia that binds to a subtype of the g-amino butyric acid type A receptor) there was an improvement in her aphasia, which allowed her to communicate using appropriately chosen words although using only fragmented sentences. The effect disappeared by the time the patient awoke the next morning but proved to be replicable whenever she took zolpidem.
Single-photon-emission computed tomography was used to measure the changes in cerebral blood flow before and after the administration of zolpidem. Baseline scans indicated moderate hypoperfusion in frontal and parietal areas surrounding the lesion, but after ingestion of zolpidem there was a 35-40% increase in blood flow to Broca's area and bilaterally to the orbitofrontal and mesial frontal cortex. The investigators concluded that zolpidem may prove an effective treatment for aphasic patients with intact but hypometabolic cortical structures, possibly following sub-cortical lesions. This finding is remarkable, but clearly requires further validation.
Conclusion
Neuropharmacological intervention can potentially help to ameliorate the cognitive effects of acquired brain injury. In the acute stage it may reduce secondary neuronal death within targeted brain areas and so help to preserve cognitive function. Patients with specific chronic cognitive deficits can benefit from the modulation of surviving neuronal networks via the targeting of specific neurotransmitters. Further studies are needed, however, to assess the most appropriate compounds and to develop methods for identifying those patients likely to benefit from specific treatments.
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